Details for Patent: 11,655,221
✉ Email this page to a colleague
Which drugs does patent 11,655,221 protect, and when does it expire?
Patent 11,655,221 protects BRINSUPRI and is included in one NDA.
This patent has eighty-eight patent family members in thirty-seven countries.
Summary for Patent: 11,655,221
| Title: | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors |
| Abstract: | The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds. |
| Inventor(s): | Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan PO KARLSSON, Carl-Johan Aurell, John Fritiof PONTÉN, Kevin James Doyle, Amanda Jane VAN DE POËL, Graham Peter Jones, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John Palmer |
| Assignee: | Biofocus DPI Ltd , AstraZeneca AB |
| Application Number: | US17/942,106 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 11,655,221
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insmed Inc | BRINSUPRI | brensocatib | TABLET;ORAL | 217673-001 | Aug 12, 2025 | RX | Yes | No | 11,655,221 | ⤷ Start Trial | Y | TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS IN PATIENTS 12 YEARS OF AGE AND OLDER | ⤷ Start Trial | |||
| Insmed Inc | BRINSUPRI | brensocatib | TABLET;ORAL | 217673-002 | Aug 12, 2025 | RX | Yes | Yes | 11,655,221 | ⤷ Start Trial | Y | TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS IN PATIENTS 12 YEARS OF AGE AND OLDER | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,655,221
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3097086 | ⤷ Start Trial | CA 2026 00019 | Denmark | ⤷ Start Trial |
| European Patent Office | 3097086 | ⤷ Start Trial | C20265009 | Finland | ⤷ Start Trial |
| European Patent Office | 3097086 | ⤷ Start Trial | LUC50047 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 3097086 | ⤷ Start Trial | 301376 | Netherlands | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
